Income StatementBalance SheetCash FlowSegments
Vertex Pharmaceuticals logo

Vertex Pharmaceuticals Business Segments

Business, geographic, and product segment breakdowns

Vertex Pharmaceuticals generates $12.2B in annual revenue across 2 key segments: Product revenues, net ($631.1M), and Royalty ($1.1B). The company-wide operating margin is 38.31%. Based on the Q1 2026 filing.

Product revenues, net (TTM)$631.1MRoyalty (TTM)$1.1B
Latest FilingQ1 2026
Report Date2026-05-05
Market Cap$110.28B
P/E Ratio25.42
ROE24.2%

Products & Services

Product revenues, net

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
TRIKAFTA/KAFTRIO$2.7B$2.5B$2.6B$2.7B$2.6B$2.4B
ALYFTREK$0.0$53.9M$156.8M$247.0M$380.1M$424.4M
Other CF product revenues$191.2M$155.3M$236.1M$175.8M$237.4M$135.9M
CASGEVY$8.0M$14.2M$30.4M$16.9M$54.3M$42.9M
JOURNAVX$0.0$1.3M$12.0M$19.6M$26.7M$29.0M

Royalty burden, percentage

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
ALYFTREK————8.0%4.0%

Cost of Sales

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Royalty$271.0M$232.4M$267.0M$275.2M$275.2M$232.6M
Product revenues, net$152.4M$130.6M$140.5M$139.6M$190.8M$160.2M

Total revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Total CF product revenues, net—$2.7B———$2.9B

Geographic

Product revenues, net

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Europe$832.0M$826.6M———$950.0M
Other$220.3M$280.1M———$261.0M

Long-term operating lease liabilities

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
New Hampshire—————$95.8M

Operating lease assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
New Hampshire—————$95.8M

Total long-lived assets

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
United Kingdom$176.6M———$167.6M—
United States$2.4B———$2.9B—

Total revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
United States$1.8B$1.7B———$1.8B

Business Segments

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Product revenues, net$2.9B$2.8B$3.0B$3.1B$3.2B$3.0B
income (loss)—$646.3M$1.0B$1.1B$1.2B$1.0B
Development expenses$791.4M$773.6M$769.1M$767.7M$771.2M$756.6M
Selling and other commercial expenses$233.6M$241.1M$264.6M$278.3M$318.8M$313.6M
Provision for income taxes$223.5M$84.1M$250.1M$215.9M$139.9M$221.5M
Research expenses$207.3M$206.1M$209.3M$210.0M$202.5M$205.0M
General and administrative expenses$144.0M$155.3M$160.0M$166.8M$168.2M$180.1M
Interest income, net—$117.9M———$114.8M
Acquired in-process research and development expenses$87.5M$19.8M$2.2M$54.5M$56.5M$500.0K
Other Segment items$16.5M$19.8M-$8.6M$11.2M$700.0K$200.0K
Intangible asset impairment charge$0.0$379.0M$0.0$0.0$0.0$0.0